NORWOOD, MA--(Marketwired - May 14, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (the "Company"), a clinical stage drug development company targeting rare, life-threatening chronic inflammatory and fibrotic diseases, announced today that it has appointed Charles N. Serhan, Ph.D., to the Company's Scientific Advisory Board ("SAB"). Dr. Serhan is a leading authority in inflammatory resolution and was the first to identify the role of anti-inflammatory cellular mediators such as resolvins and lipoxins in the pro-inflammatory pathway.
"We are honored and delighted to have Dr. Serhan join our SAB," commented Mark A. Tepper, Ph.D., President and Chief Scientific Officer of the Company. "As a renowned expert in the molecular and cellular basis of inflammation and given his role in elucidating the mechanism of inflammation and its resolution, we look forward to the added scientific guidance and collaborative opportunities with Dr. Serhan as we explore the clinical benefits of Resunab™ in individuals with cystic fibrosis and systemic sclerosis while continuing to expand our understanding of its unique mechanism of action."
Dr. Serhan is the first Endowed Distinguished Scientist at Brigham and Women's Hospital ("BWH") and since 1995 has served as Director of the Center for Experimental Therapeutics and Reperfusion Injury ("CET&RI") at BWH. He is a full Professor of Anaesthesia at Harvard Medical School and is also affiliated with its Department of Biological Chemistry and Molecular Pharmacology. Additionally, Dr. Serhan is the Simon Gelman Professor of Anesthesia, Perioperative and Pain Medicine (Biochemistry & Molecular Pharmacology) at Harvard Medical School and Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine.
At CET&RI, Dr. Serhan serves as the Director and Principal Investigator of the Serhan Laboratory and the program director of a federally supported National Institutes of Health ("NIH") Program Project grant on the Resolution Mechanisms in Acute Inflammation: Resolution Pharmacology. He is also Principal Investigator on the NIH research grant entitled, Blood Cell Lipoxygenase Products: Formation and Action, funded since 1987 and honored with a MERIT Award. The research undertaken in the Serhan Laboratory focuses on structural elucidation of bioactive molecules in inflammation. The lab's overall mission is to identify novel bioactive mediators, pathways, and cellular targets critical in activating resolution of inflammation and their relation to human disease. Most recent studies undertaken by the Serhan Laboratory focus on structural elucidation of novel molecules and pathways that serve as pro-resolving and/or endogenous anti-inflammatory chemical signals.
"Uncontrolled inflammation is a unifying pathophysiologic basis for many widely occurring chronic diseases, including the rare, life-threatening inflammatory and fibrotic diseases at the heart of Corbus' clinical development focus," added Dr. Serhan. "Resunab's ability to activate inflammatory resolution mechanisms and the return of tissues to homeostasis following inflammatory challenge offers a real potential for life-changing, breakthrough therapy not only for cystic fibrosis and scleroderma, but also for many other diseases with high unmet medical need in which chronic inflammation and fibrosis are present."
Dr. Serhan is the recipient of numerous honors including a MERIT Award from the National Institute of General Medical Sciences, The American Heart Established Investigatorship award, a prestigious Pew Scholar in the biomedical sciences, the MacArthur Research Service Award and an Outstanding Scientist Award in Inflammation. He is a member of several societies and editorial boards, including the American Society for Biochemistry and Molecular Biology, Inflammation (Associate Editor), American Society for Pharmacology and Experimental Therapeutics, American Association of Immunologists, American Society for Investigative Pathology, the Journal of Experimental Medicine (Editorial Board), and has served on the Foundation for the NIH Biomarkers Consortium since 2007. Additionally, Dr. Serhan has authored more than 400 scientific publications, written several books, and has been awarded more than 200 patents.
Dr. Serhan earned his Bachelor's degree in biochemistry from Stony Brook University New York, and his doctorate in Experimental Pathology and Medical Sciences from New York University School of Medicine. He completed his post-doctoral training in Physiological Chemistry at the Karolinska Institute Medical University with Professor Bengt Samuelsson, the 1982 Nobel Laureate in Medicine, and later received an honorary degree from Harvard University.
Resunab™ is a novel synthetic oral drug with unique activity that has been shown to resolve inflammation and pro-fibrotic processes. Pre-clinical models and Phase 1 clinical studies have shown Resunab to have a favorable safety profile coupled with promising potency in pre-clinical models of inflammation and fibrosis. Resunab binds to the CB2 receptor on immune cells and triggers resolution of inflammation and reduction of pro-inflammatory pathways, in effect turning chronic inflammation "off" without causing immunosuppression.
About Corbus Pharmaceuticals
Corbus Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. Our lead product candidate Resunab™ is a novel oral drug that resolves chronic inflammation and pro-fibrotic processes. Resunab is scheduled to commence Phase 2 clinical trials for the treatment of cystic fibrosis and diffuse cutaneous systemic sclerosis (scleroderma) in 2015. For more information, please visit www.CorbusPharma.com.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Relations and Corporate Communications Advisor
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: Email Contact
David Schull or Marissa Goberdhan
Russo Partners, LLC
Phone: +1 (858) 717-2310
Email: Email Contact
Email: Email Contact